Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;9(4):197-202.
doi: 10.1016/j.prnil.2021.05.001. Epub 2021 May 29.

Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study

Hyun Kyu Ahn  1 , Hye Sun Lee  2 , Ju-Young Park  3 , Do Kyung Kim  4 , Min Kim  5 , Ho Sik Hwang  6 , Jong Won Kim  7 , Jee Soo Ha  8 , Kang Su Cho  8
Affiliations

Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study

Hyun Kyu Ahn et al. Prostate Int. 2021 Dec.

Abstract

Background: We evaluated the risk of developing primary open-angle glaucoma (POAG) according to androgen deprivation therapy (ADT) status in patients with prostate cancer.

Materials and methods: From the nationwide claims database in South Korea, 218,203 men with prostate cancer were identified between 2008 and 2017. After applying the inclusion and exclusion criteria, a total of 170,701 patients (42,877 in the ADT and non-ADT groups and 127,824 in the non-ADT group) were included in the analysis. To adjust for comorbidities between cohorts, exact matching was performed. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of POAG associated with ADT after controlling for potential confounding factors.

Results: In the matched cohort, the ADT group had a lower proportion of newly developed POAG than the non-ADT group (2.10% vs. 2.88%, respectively; P < 0.0001). Multivariable analysis revealed that the ADT group had a significantly lower risk of POAG than the non-ADT group (HR, 0.808; 95% CI, 0.739-0.884; P < 0.0001). The risk of POAG was lower in patients who underwent ADT for less than 2 years (HR, 0.782; 95% CI, 0.690-0.886; P = 0.0001) and in those receiving ADT for over 2 years (HR, 0.825; 95% CI, 0.744-0.916; P = 0.0003) compared with the non-ADT group.

Conclusions: The use of ADT was associated with a decreased risk of POAG in Korean patients with prostate cancer. Our findings suggest that testosterone may be involved in the pathophysiology of POAG, and this should be confirmed through further studies.

Keywords: Glaucoma; Prostate cancer; Testosterone.

PubMed Disclaimer

Conflict of interest statement

All of the authors declare that they have no conflict of interests to declare.

Figures

Fig. 1
Fig. 1
Flow diagram of the study cohort. ADT, androgen deprivation therapy.
Fig. 2
Fig. 2
Cumulative incidence of primary open-angle glaucoma according to the use of ADT (A) and the duration of ADT (B). ADT, androgen deprivation therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89. - PMC - PubMed
    1. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. - PubMed
    1. Ahn S., Lee M., Jeong C.W. Comparative quality-adjusted survival analysis between radiation therapy alone and radiation with androgen deprivation therapy in patients with locally advanced prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 85-31 with novel decision analysis methods. Prostate Int. 2018;6(4):140–144. - PMC - PubMed
    1. Warde P., Mason M., Ding K., Kirkbride P., Brundage M., Cowan R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. - PMC - PubMed
    1. Borno H.T., Lichtensztajn D.Y., Gomez S.L., Palmer N.R., Ryan C.J. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2019;125(3):453–462. - PMC - PubMed